Pharmacokinetic and exploratory exposure-response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study. View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-04-11

AUTHORS

Whitney P Kirschbrown, Matts Kågedal, Bei Wang, Lars Lindbom, Adam Knott, Rachelle Mack, Sharareh Monemi, Ihsan Nijem, Sandhya Girish, Christie Freeman, Debora Fumagalli, Robin McConnell, Guy Jerusalem, Chris Twelves, José Baselga, Gunter von Minckwitz, José Bines, Amit Garg

ABSTRACT

PURPOSE: To characterize the pharmacokinetics (PK) of, and perform an exploratory exposure-response (E-R) analysis for, pertuzumab in patients with HER2-positive early breast cancer (EBC) within the APHINITY study (NCT01358877, BIG 4-11/BO25126/TOC4939G). METHODS: A previously developed pertuzumab two-compartment linear population pharmacokinetic (popPK) model was subjected to external validation to examine appropriateness for describing pertuzumab concentrations from the APHINITY study. Pharmacokinetic drug-drug interactions (DDIs) between pertuzumab, trastuzumab, and chemotherapy were assessed by comparing observed serum or plasma Cmax, Cmin, and AUClast geometric mean ratios with 90% CIs. Predictions of pertuzumab Cmax,ss, Cmin,ss, and AUCss were derived from individual parameter estimates and used in an exploratory E-R analysis. RESULTS: Using data from 72 patients, based on goodness-of-fit, the popPK model was deemed appropriate for predictions of individual exposures for subsequent comparisons to historical data, assessment of DDIs, and E-R analyses. No evidence of DDIs for pertuzumab on trastuzumab, trastuzumab on pertuzumab, or pertuzumab on chemotherapy PK was observed. Analyses of differences in exposure between patients with and without invasive disease-free survival events did not indicate improved efficacy with increased exposure. Overall Grade ≥ 3 diarrhea prevalence was higher with pertuzumab versus placebo, but was not greater with increasing pertuzumab exposure. No apparent E-R relationship was suggested with respect to other grade ≥ 3 AEs. CONCLUSION: Overall, the limited available data from this exploratory study suggest that no dose adjustments are needed for pertuzumab when administered in combination with trastuzumab and an EBC chemotherapy regimen. More... »

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00280-019-03826-1

DOI

http://dx.doi.org/10.1007/s00280-019-03826-1

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1113378441

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30976844


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Roche (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418158.1", 
          "name": [
            "Genentech, 1 DNA Way, South San Francisco, CA, 94080, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kirschbrown", 
        "givenName": "Whitney P", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Roche (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418158.1", 
          "name": [
            "Genentech, 1 DNA Way, South San Francisco, CA, 94080, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "K\u00e5gedal", 
        "givenName": "Matts", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Roche (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418158.1", 
          "name": [
            "Genentech, 1 DNA Way, South San Francisco, CA, 94080, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wang", 
        "givenName": "Bei", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "qPharmetra, H\u00e4lsov\u00e4gen 7, 141 57, Huddinge, Sweden."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lindbom", 
        "givenName": "Lars", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Roche (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.419227.b", 
          "name": [
            "Roche Products Limited, 6 Falcon Way, Shire Park, Welwyn Garden City, AL7 1TW, UK."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Knott", 
        "givenName": "Adam", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Roche (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.419227.b", 
          "name": [
            "Roche Products Limited, 6 Falcon Way, Shire Park, Welwyn Garden City, AL7 1TW, UK."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mack", 
        "givenName": "Rachelle", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Roche (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418158.1", 
          "name": [
            "Genentech, 1 DNA Way, South San Francisco, CA, 94080, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Monemi", 
        "givenName": "Sharareh", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Roche (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418158.1", 
          "name": [
            "Genentech, 1 DNA Way, South San Francisco, CA, 94080, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nijem", 
        "givenName": "Ihsan", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Roche (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418158.1", 
          "name": [
            "Genentech, 1 DNA Way, South San Francisco, CA, 94080, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Girish", 
        "givenName": "Sandhya", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut Jules Bordet", 
          "id": "https://www.grid.ac/institutes/grid.418119.4", 
          "name": [
            "Breast European Adjuvant Study Team (BrEAST) Data Center, Institut Jules Bordet, Boulevard de Waterloo 121 (7th Floor), 1000, Brussels, Belgium."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Freeman", 
        "givenName": "Christie", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Breast International Group", 
          "id": "https://www.grid.ac/institutes/grid.427828.3", 
          "name": [
            "Breast International Group, Boulevard de Waterloo 76, 1000, Brussels, Belgium."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fumagalli", 
        "givenName": "Debora", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Frontier Science (Scotland), Grampian View, Kincraig, Inverness-Shire, PH21 1NA, UK."
          ], 
          "type": "Organization"
        }, 
        "familyName": "McConnell", 
        "givenName": "Robin", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Li\u00e8ge", 
          "id": "https://www.grid.ac/institutes/grid.4861.b", 
          "name": [
            "International Breast Cancer Study Group, CHU Li\u00e8ge and Li\u00e8ge University, Domaine Universitaire du Sart Tilman, B35, 4000, Li\u00e8ge, Belgium."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jerusalem", 
        "givenName": "Guy", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "St James's University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.443984.6", 
          "name": [
            "University of Leeds and Leeds Teaching Hospitals Trust, St James's University Hospital, Beckett Street, Leeds, LS9 7TF, UK."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Twelves", 
        "givenName": "Chris", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418152.b", 
          "name": [
            "Executive Vice-President Research & Development Oncology, AstraZeneca, 950 Wind River Ln, Gaithersburg, MD, 20878, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Baselga", 
        "givenName": "Jos\u00e9", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "German Breast group", 
          "id": "https://www.grid.ac/institutes/grid.434440.3", 
          "name": [
            "German Breast Group, GBG Forschungs, Martin-Behaim-Str. 12, 63263, Neu-Isenburg, Germany."
          ], 
          "type": "Organization"
        }, 
        "familyName": "von Minckwitz", 
        "givenName": "Gunter", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Instituto Nacional do C\u00e2ncer", 
          "id": "https://www.grid.ac/institutes/grid.419166.d", 
          "name": [
            "Instituto Nacional de C\u00e2ncer, Pra\u00e7a Cruz Vermelha, 23-Centro, Rio de Janeiro, 20230-130, Brazil."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bines", 
        "givenName": "Jos\u00e9", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Roche (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418158.1", 
          "name": [
            "Genentech, 1 DNA Way, South San Francisco, CA, 94080, USA. garg.amit@gene.com."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Garg", 
        "givenName": "Amit", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00280-014-2560-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004783955", 
          "https://doi.org/10.1007/s00280-014-2560-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(11)70336-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006777850"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1535-6108(02)00097-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009224253"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1535-6108(02)00097-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009224253"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-015-2922-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011349790", 
          "https://doi.org/10.1007/s00280-015-2922-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-015-2922-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011349790", 
          "https://doi.org/10.1007/s00280-015-2922-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1113216", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013126608"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1196/annals.1430.003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018747152"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/cad.0000000000000016", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030996000"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/cad.0000000000000016", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030996000"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/11531280-000000000-00000", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033453107", 
          "https://doi.org/10.2165/11531280-000000000-00000"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/11531280-000000000-00000", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033453107", 
          "https://doi.org/10.2165/11531280-000000000-00000"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc2656", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035598015", 
          "https://doi.org/10.1038/nrc2656"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc2656", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035598015", 
          "https://doi.org/10.1038/nrc2656"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00262-005-0058-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038243318", 
          "https://doi.org/10.1007/s00262-005-0058-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00262-005-0058-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038243318", 
          "https://doi.org/10.1007/s00262-005-0058-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-016-3218-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044012265", 
          "https://doi.org/10.1007/s00280-016-3218-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-016-3218-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044012265", 
          "https://doi.org/10.1007/s00280-016-3218-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003088-199121040-00002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047951045", 
          "https://doi.org/10.2165/00003088-199121040-00002"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdt182", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049729330"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003088-199427040-00002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053348338", 
          "https://doi.org/10.2165/00003088-199427040-00002"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003088-199427040-00002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053348338", 
          "https://doi.org/10.2165/00003088-199427040-00002"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/35052073", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053565592", 
          "https://doi.org/10.1038/35052073"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/35052073", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053565592", 
          "https://doi.org/10.1038/35052073"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/35052073", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053565592", 
          "https://doi.org/10.1038/35052073"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.can-08-4597", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053676255"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2174/138920012802138688", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1069176119"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1703643", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085866538"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4155/bio-2018-0196", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1107648936"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-04-11", 
    "datePublishedReg": "2019-04-11", 
    "description": "PURPOSE: To characterize the pharmacokinetics (PK) of, and perform an exploratory exposure-response (E-R) analysis for, pertuzumab in patients with HER2-positive early breast cancer (EBC) within the APHINITY study (NCT01358877, BIG 4-11/BO25126/TOC4939G).\nMETHODS: A previously developed pertuzumab two-compartment linear population pharmacokinetic (popPK) model was subjected to external validation to examine appropriateness for describing pertuzumab concentrations from the APHINITY study. Pharmacokinetic drug-drug interactions (DDIs) between pertuzumab, trastuzumab, and chemotherapy were assessed by comparing observed serum or plasma Cmax, Cmin, and AUClast geometric mean ratios with 90% CIs. Predictions of pertuzumab Cmax,ss, Cmin,ss, and AUCss were derived from individual parameter estimates and used in an exploratory E-R analysis.\nRESULTS: Using data from 72 patients, based on goodness-of-fit, the popPK model was deemed appropriate for predictions of individual exposures for subsequent comparisons to historical data, assessment of DDIs, and E-R analyses. No evidence of DDIs for pertuzumab on trastuzumab, trastuzumab on pertuzumab, or pertuzumab on chemotherapy PK was observed. Analyses of differences in exposure between patients with and without invasive disease-free survival events did not indicate improved efficacy with increased exposure. Overall Grade\u2009\u2265\u20093 diarrhea prevalence was higher with pertuzumab versus placebo, but was not greater with increasing pertuzumab exposure. No apparent E-R relationship was suggested with respect to other grade\u2009\u2265\u20093 AEs.\nCONCLUSION: Overall, the limited available data from this exploratory study suggest that no dose adjustments are needed for pertuzumab when administered in combination with trastuzumab and an EBC chemotherapy regimen.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00280-019-03826-1", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1088364", 
        "issn": [
          "0344-5704", 
          "1432-0843"
        ], 
        "name": "Cancer Chemotherapy and Pharmacology", 
        "type": "Periodical"
      }
    ], 
    "name": "Pharmacokinetic and exploratory exposure-response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study.", 
    "productId": [
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00280-019-03826-1"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1113378441"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "7806519"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30976844"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00280-019-03826-1", 
      "https://app.dimensions.ai/details/publication/pub.1113378441"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-16T06:25", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000377_0000000377/records_106834_00000003.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/s00280-019-03826-1"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00280-019-03826-1'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00280-019-03826-1'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00280-019-03826-1'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00280-019-03826-1'


 

This table displays all metadata directly associated to this object as RDF triples.

254 TRIPLES      20 PREDICATES      43 URIs      16 LITERALS      6 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00280-019-03826-1 schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author Nd922141299cb49d2bc5027deebbb89bc
4 schema:citation sg:pub.10.1007/s00262-005-0058-x
5 sg:pub.10.1007/s00280-014-2560-3
6 sg:pub.10.1007/s00280-015-2922-5
7 sg:pub.10.1007/s00280-016-3218-0
8 sg:pub.10.1038/35052073
9 sg:pub.10.1038/nrc2656
10 sg:pub.10.2165/00003088-199121040-00002
11 sg:pub.10.2165/00003088-199427040-00002
12 sg:pub.10.2165/11531280-000000000-00000
13 https://doi.org/10.1016/s1470-2045(11)70336-9
14 https://doi.org/10.1016/s1535-6108(02)00097-1
15 https://doi.org/10.1056/nejmoa1113216
16 https://doi.org/10.1056/nejmoa1703643
17 https://doi.org/10.1093/annonc/mdt182
18 https://doi.org/10.1097/cad.0000000000000016
19 https://doi.org/10.1158/0008-5472.can-08-4597
20 https://doi.org/10.1196/annals.1430.003
21 https://doi.org/10.2174/138920012802138688
22 https://doi.org/10.4155/bio-2018-0196
23 schema:datePublished 2019-04-11
24 schema:datePublishedReg 2019-04-11
25 schema:description PURPOSE: To characterize the pharmacokinetics (PK) of, and perform an exploratory exposure-response (E-R) analysis for, pertuzumab in patients with HER2-positive early breast cancer (EBC) within the APHINITY study (NCT01358877, BIG 4-11/BO25126/TOC4939G). METHODS: A previously developed pertuzumab two-compartment linear population pharmacokinetic (popPK) model was subjected to external validation to examine appropriateness for describing pertuzumab concentrations from the APHINITY study. Pharmacokinetic drug-drug interactions (DDIs) between pertuzumab, trastuzumab, and chemotherapy were assessed by comparing observed serum or plasma Cmax, Cmin, and AUClast geometric mean ratios with 90% CIs. Predictions of pertuzumab Cmax,ss, Cmin,ss, and AUCss were derived from individual parameter estimates and used in an exploratory E-R analysis. RESULTS: Using data from 72 patients, based on goodness-of-fit, the popPK model was deemed appropriate for predictions of individual exposures for subsequent comparisons to historical data, assessment of DDIs, and E-R analyses. No evidence of DDIs for pertuzumab on trastuzumab, trastuzumab on pertuzumab, or pertuzumab on chemotherapy PK was observed. Analyses of differences in exposure between patients with and without invasive disease-free survival events did not indicate improved efficacy with increased exposure. Overall Grade ≥ 3 diarrhea prevalence was higher with pertuzumab versus placebo, but was not greater with increasing pertuzumab exposure. No apparent E-R relationship was suggested with respect to other grade ≥ 3 AEs. CONCLUSION: Overall, the limited available data from this exploratory study suggest that no dose adjustments are needed for pertuzumab when administered in combination with trastuzumab and an EBC chemotherapy regimen.
26 schema:genre research_article
27 schema:inLanguage en
28 schema:isAccessibleForFree false
29 schema:isPartOf sg:journal.1088364
30 schema:name Pharmacokinetic and exploratory exposure-response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study.
31 schema:productId N89280314a30541058ec35a10af49ec45
32 Nb2c27002c15c4c5992a248b7154bcd35
33 Nc30b4394e8f14b2b8192d3c9f92fb624
34 Nf064fd4c520846d7ad5af5640dc8f7cf
35 schema:sameAs https://app.dimensions.ai/details/publication/pub.1113378441
36 https://doi.org/10.1007/s00280-019-03826-1
37 schema:sdDatePublished 2019-04-16T06:25
38 schema:sdLicense https://scigraph.springernature.com/explorer/license/
39 schema:sdPublisher Nc6dc8fa4aa0549afa39a5160e6f75ac0
40 schema:url http://link.springer.com/10.1007/s00280-019-03826-1
41 sgo:license sg:explorer/license/
42 sgo:sdDataset articles
43 rdf:type schema:ScholarlyArticle
44 N07f89d1b3a6846fcb04b29e9addfadbd schema:affiliation https://www.grid.ac/institutes/grid.443984.6
45 schema:familyName Twelves
46 schema:givenName Chris
47 rdf:type schema:Person
48 N126300044f6a47a3bc7bad6f7a0c83e9 rdf:first Ncfa1d0aa0dca49b58b7bbeb84d422dd8
49 rdf:rest N45b15290846d482c9e2f8a59a7b558f2
50 N12bd55c6fe234945a28dacb674c20ef5 rdf:first N364f6ec79a7a4496b8edd778c5f46d50
51 rdf:rest N761b5d7151604756a9e85150c049c0bf
52 N1447125ec3aa4dacab0b22b167f0369b schema:affiliation https://www.grid.ac/institutes/grid.418119.4
53 schema:familyName Freeman
54 schema:givenName Christie
55 rdf:type schema:Person
56 N1e33576172774ddab4b0c921996921c4 rdf:first N3aa15f72a2074578b3d9bbc208dae4ba
57 rdf:rest N3b30c3479ba74bdaaa3204dc2d558413
58 N2ddb55fcf0084e20a029ed36249c37a8 rdf:first Ndb8a4ac394514bad9a898a8baee2a775
59 rdf:rest N12bd55c6fe234945a28dacb674c20ef5
60 N364f6ec79a7a4496b8edd778c5f46d50 schema:affiliation N83bd9fadb3ea45a28bd31050a382c7d7
61 schema:familyName Lindbom
62 schema:givenName Lars
63 rdf:type schema:Person
64 N3aa15f72a2074578b3d9bbc208dae4ba schema:affiliation https://www.grid.ac/institutes/grid.4861.b
65 schema:familyName Jerusalem
66 schema:givenName Guy
67 rdf:type schema:Person
68 N3b30c3479ba74bdaaa3204dc2d558413 rdf:first N07f89d1b3a6846fcb04b29e9addfadbd
69 rdf:rest N432faf64a11d42aeb08b1af1ccb38d11
70 N432faf64a11d42aeb08b1af1ccb38d11 rdf:first N8ce5d7f13cc84f8f83937ed74935f7e1
71 rdf:rest N126300044f6a47a3bc7bad6f7a0c83e9
72 N458279aee37a4f3392ca54fefc7d6e22 rdf:first Nbea8463a737a41df884586a4b14e5473
73 rdf:rest N60ffc78b7d724edb9720f5bbd9e717ae
74 N45b15290846d482c9e2f8a59a7b558f2 rdf:first Nfcd4b3fe73d84287aab8e909996d1e7e
75 rdf:rest N775219de789241a0b0673e639dc184fd
76 N47e80ee90111427c97f816e73209d414 schema:affiliation https://www.grid.ac/institutes/grid.419227.b
77 schema:familyName Mack
78 schema:givenName Rachelle
79 rdf:type schema:Person
80 N49f6b3fe8f6b474aa0aa1f48f5da84e2 schema:name Frontier Science (Scotland), Grampian View, Kincraig, Inverness-Shire, PH21 1NA, UK.
81 rdf:type schema:Organization
82 N60ffc78b7d724edb9720f5bbd9e717ae rdf:first Ne1678c2e159c48ce8c7e94d28fee01e2
83 rdf:rest Nb379fb62ebff42da919a164893676556
84 N63813a62996d4d97ad072c41804f34f7 schema:affiliation https://www.grid.ac/institutes/grid.418158.1
85 schema:familyName Garg
86 schema:givenName Amit
87 rdf:type schema:Person
88 N6cfd00cce7a547679ce5fdcae2434446 schema:affiliation N49f6b3fe8f6b474aa0aa1f48f5da84e2
89 schema:familyName McConnell
90 schema:givenName Robin
91 rdf:type schema:Person
92 N761b5d7151604756a9e85150c049c0bf rdf:first Ne55358ed8d9c499ab193264d28a5f4fe
93 rdf:rest Nf3c1a76b1b93428b82f8cf1f350b2054
94 N775219de789241a0b0673e639dc184fd rdf:first N63813a62996d4d97ad072c41804f34f7
95 rdf:rest rdf:nil
96 N810e8e1ca2364561b893f812e1134c3f schema:affiliation https://www.grid.ac/institutes/grid.418158.1
97 schema:familyName Girish
98 schema:givenName Sandhya
99 rdf:type schema:Person
100 N83bd9fadb3ea45a28bd31050a382c7d7 schema:name qPharmetra, Hälsovägen 7, 141 57, Huddinge, Sweden.
101 rdf:type schema:Organization
102 N89280314a30541058ec35a10af49ec45 schema:name pubmed_id
103 schema:value 30976844
104 rdf:type schema:PropertyValue
105 N8ce5d7f13cc84f8f83937ed74935f7e1 schema:affiliation https://www.grid.ac/institutes/grid.418152.b
106 schema:familyName Baselga
107 schema:givenName José
108 rdf:type schema:Person
109 N8f56eb21af864c97893fde8fe02bfe70 schema:affiliation https://www.grid.ac/institutes/grid.418158.1
110 schema:familyName Kågedal
111 schema:givenName Matts
112 rdf:type schema:Person
113 N9b7274373f9a4a77a8f042cebad16f99 rdf:first N1447125ec3aa4dacab0b22b167f0369b
114 rdf:rest Nd80dd1f853d947ee8de9cb0653efd2df
115 Na0760be879c54520940dcb02f66a112f schema:affiliation https://www.grid.ac/institutes/grid.418158.1
116 schema:familyName Kirschbrown
117 schema:givenName Whitney P
118 rdf:type schema:Person
119 Na5b7a2cf752947ed8194dbe3b11c7684 rdf:first N8f56eb21af864c97893fde8fe02bfe70
120 rdf:rest N2ddb55fcf0084e20a029ed36249c37a8
121 Nb2c27002c15c4c5992a248b7154bcd35 schema:name nlm_unique_id
122 schema:value 7806519
123 rdf:type schema:PropertyValue
124 Nb379fb62ebff42da919a164893676556 rdf:first N810e8e1ca2364561b893f812e1134c3f
125 rdf:rest N9b7274373f9a4a77a8f042cebad16f99
126 Nbea8463a737a41df884586a4b14e5473 schema:affiliation https://www.grid.ac/institutes/grid.418158.1
127 schema:familyName Monemi
128 schema:givenName Sharareh
129 rdf:type schema:Person
130 Nc30b4394e8f14b2b8192d3c9f92fb624 schema:name dimensions_id
131 schema:value pub.1113378441
132 rdf:type schema:PropertyValue
133 Nc6dc8fa4aa0549afa39a5160e6f75ac0 schema:name Springer Nature - SN SciGraph project
134 rdf:type schema:Organization
135 Ncfa1d0aa0dca49b58b7bbeb84d422dd8 schema:affiliation https://www.grid.ac/institutes/grid.434440.3
136 schema:familyName von Minckwitz
137 schema:givenName Gunter
138 rdf:type schema:Person
139 Nd80dd1f853d947ee8de9cb0653efd2df rdf:first Nfd296a235e5840fcbebd3891c523242e
140 rdf:rest Ne6c2480c0e764cfca269256b71f1955a
141 Nd922141299cb49d2bc5027deebbb89bc rdf:first Na0760be879c54520940dcb02f66a112f
142 rdf:rest Na5b7a2cf752947ed8194dbe3b11c7684
143 Ndb8a4ac394514bad9a898a8baee2a775 schema:affiliation https://www.grid.ac/institutes/grid.418158.1
144 schema:familyName Wang
145 schema:givenName Bei
146 rdf:type schema:Person
147 Ne1678c2e159c48ce8c7e94d28fee01e2 schema:affiliation https://www.grid.ac/institutes/grid.418158.1
148 schema:familyName Nijem
149 schema:givenName Ihsan
150 rdf:type schema:Person
151 Ne55358ed8d9c499ab193264d28a5f4fe schema:affiliation https://www.grid.ac/institutes/grid.419227.b
152 schema:familyName Knott
153 schema:givenName Adam
154 rdf:type schema:Person
155 Ne6c2480c0e764cfca269256b71f1955a rdf:first N6cfd00cce7a547679ce5fdcae2434446
156 rdf:rest N1e33576172774ddab4b0c921996921c4
157 Nf064fd4c520846d7ad5af5640dc8f7cf schema:name doi
158 schema:value 10.1007/s00280-019-03826-1
159 rdf:type schema:PropertyValue
160 Nf3c1a76b1b93428b82f8cf1f350b2054 rdf:first N47e80ee90111427c97f816e73209d414
161 rdf:rest N458279aee37a4f3392ca54fefc7d6e22
162 Nfcd4b3fe73d84287aab8e909996d1e7e schema:affiliation https://www.grid.ac/institutes/grid.419166.d
163 schema:familyName Bines
164 schema:givenName José
165 rdf:type schema:Person
166 Nfd296a235e5840fcbebd3891c523242e schema:affiliation https://www.grid.ac/institutes/grid.427828.3
167 schema:familyName Fumagalli
168 schema:givenName Debora
169 rdf:type schema:Person
170 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
171 schema:name Medical and Health Sciences
172 rdf:type schema:DefinedTerm
173 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
174 schema:name Oncology and Carcinogenesis
175 rdf:type schema:DefinedTerm
176 sg:journal.1088364 schema:issn 0344-5704
177 1432-0843
178 schema:name Cancer Chemotherapy and Pharmacology
179 rdf:type schema:Periodical
180 sg:pub.10.1007/s00262-005-0058-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1038243318
181 https://doi.org/10.1007/s00262-005-0058-x
182 rdf:type schema:CreativeWork
183 sg:pub.10.1007/s00280-014-2560-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004783955
184 https://doi.org/10.1007/s00280-014-2560-3
185 rdf:type schema:CreativeWork
186 sg:pub.10.1007/s00280-015-2922-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011349790
187 https://doi.org/10.1007/s00280-015-2922-5
188 rdf:type schema:CreativeWork
189 sg:pub.10.1007/s00280-016-3218-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044012265
190 https://doi.org/10.1007/s00280-016-3218-0
191 rdf:type schema:CreativeWork
192 sg:pub.10.1038/35052073 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053565592
193 https://doi.org/10.1038/35052073
194 rdf:type schema:CreativeWork
195 sg:pub.10.1038/nrc2656 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035598015
196 https://doi.org/10.1038/nrc2656
197 rdf:type schema:CreativeWork
198 sg:pub.10.2165/00003088-199121040-00002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047951045
199 https://doi.org/10.2165/00003088-199121040-00002
200 rdf:type schema:CreativeWork
201 sg:pub.10.2165/00003088-199427040-00002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053348338
202 https://doi.org/10.2165/00003088-199427040-00002
203 rdf:type schema:CreativeWork
204 sg:pub.10.2165/11531280-000000000-00000 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033453107
205 https://doi.org/10.2165/11531280-000000000-00000
206 rdf:type schema:CreativeWork
207 https://doi.org/10.1016/s1470-2045(11)70336-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006777850
208 rdf:type schema:CreativeWork
209 https://doi.org/10.1016/s1535-6108(02)00097-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009224253
210 rdf:type schema:CreativeWork
211 https://doi.org/10.1056/nejmoa1113216 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013126608
212 rdf:type schema:CreativeWork
213 https://doi.org/10.1056/nejmoa1703643 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085866538
214 rdf:type schema:CreativeWork
215 https://doi.org/10.1093/annonc/mdt182 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049729330
216 rdf:type schema:CreativeWork
217 https://doi.org/10.1097/cad.0000000000000016 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030996000
218 rdf:type schema:CreativeWork
219 https://doi.org/10.1158/0008-5472.can-08-4597 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053676255
220 rdf:type schema:CreativeWork
221 https://doi.org/10.1196/annals.1430.003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018747152
222 rdf:type schema:CreativeWork
223 https://doi.org/10.2174/138920012802138688 schema:sameAs https://app.dimensions.ai/details/publication/pub.1069176119
224 rdf:type schema:CreativeWork
225 https://doi.org/10.4155/bio-2018-0196 schema:sameAs https://app.dimensions.ai/details/publication/pub.1107648936
226 rdf:type schema:CreativeWork
227 https://www.grid.ac/institutes/grid.418119.4 schema:alternateName Institut Jules Bordet
228 schema:name Breast European Adjuvant Study Team (BrEAST) Data Center, Institut Jules Bordet, Boulevard de Waterloo 121 (7th Floor), 1000, Brussels, Belgium.
229 rdf:type schema:Organization
230 https://www.grid.ac/institutes/grid.418152.b schema:alternateName AstraZeneca (United States)
231 schema:name Executive Vice-President Research & Development Oncology, AstraZeneca, 950 Wind River Ln, Gaithersburg, MD, 20878, USA.
232 rdf:type schema:Organization
233 https://www.grid.ac/institutes/grid.418158.1 schema:alternateName Roche (United States)
234 schema:name Genentech, 1 DNA Way, South San Francisco, CA, 94080, USA.
235 Genentech, 1 DNA Way, South San Francisco, CA, 94080, USA. garg.amit@gene.com.
236 rdf:type schema:Organization
237 https://www.grid.ac/institutes/grid.419166.d schema:alternateName Instituto Nacional do Câncer
238 schema:name Instituto Nacional de Câncer, Praça Cruz Vermelha, 23-Centro, Rio de Janeiro, 20230-130, Brazil.
239 rdf:type schema:Organization
240 https://www.grid.ac/institutes/grid.419227.b schema:alternateName Roche (United Kingdom)
241 schema:name Roche Products Limited, 6 Falcon Way, Shire Park, Welwyn Garden City, AL7 1TW, UK.
242 rdf:type schema:Organization
243 https://www.grid.ac/institutes/grid.427828.3 schema:alternateName Breast International Group
244 schema:name Breast International Group, Boulevard de Waterloo 76, 1000, Brussels, Belgium.
245 rdf:type schema:Organization
246 https://www.grid.ac/institutes/grid.434440.3 schema:alternateName German Breast group
247 schema:name German Breast Group, GBG Forschungs, Martin-Behaim-Str. 12, 63263, Neu-Isenburg, Germany.
248 rdf:type schema:Organization
249 https://www.grid.ac/institutes/grid.443984.6 schema:alternateName St James's University Hospital
250 schema:name University of Leeds and Leeds Teaching Hospitals Trust, St James's University Hospital, Beckett Street, Leeds, LS9 7TF, UK.
251 rdf:type schema:Organization
252 https://www.grid.ac/institutes/grid.4861.b schema:alternateName University of Liège
253 schema:name International Breast Cancer Study Group, CHU Liège and Liège University, Domaine Universitaire du Sart Tilman, B35, 4000, Liège, Belgium.
254 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...